Literature DB >> 3805763

Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus.

R D Arbeit, M J Nelles.   

Abstract

In vivo expression of the type 8 capsular polysaccharide (CP) of Staphylococcus aureus was studied in the rat model of aortic valve endocarditis. An enzyme-linked immunosorbent assay (ELISA) with monoclonal antibodies to type 8 CP was sensitive to 0.16 ng/ml in serum. All (23 of 23) animals infected with the prototype type 8 strain Becker had CP detected in one or more serum samples. Peak CP levels ranged from 0.16 to 240 ng/ml (median, 25 ng/ml). Among the 14 rats alive on day 2, antigenemia and bacteremia were significantly correlated (r = .71, P less than .005). CP was also present in serum of rats infected with three additional type 8 bacteremic isolates. All serum samples from animals infected with the type 5 prototype strain were negative in the type 8 ELISA. These studies document that the type 8 CP of S. aureus, previously identified only in vitro, is produced and released during in vivo infection and can be detected in serum of infected animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3805763     DOI: 10.1093/infdis/155.2.242

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains.

Authors:  B Poutrel; F B Gilbert; M Lebrun
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

Review 2.  Virulence factors among gram-positive bacteria in experimental endocarditis.

Authors:  L M Baddour
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

3.  Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.

Authors:  Bo Liu; Saeyoung Park; Christopher D Thompson; Xue Li; Jean C Lee
Journal:  Virulence       Date:  2016-12-09       Impact factor: 5.882

4.  Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.

Authors:  A Albus; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 5.  Staphylococcus aureus capsular polysaccharides.

Authors:  Katherine O'Riordan; Jean C Lee
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

6.  Capsular polysaccharide types 5 and 8 of Staphylococcus aureus bind specifically to human epithelial (KB) cells, endothelial cells, and monocytes and induce release of cytokines.

Authors:  M Soell; M Diab; G Haan-Archipoff; A Beretz; C Herbelin; B Poutrel; J P Klein
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

7.  Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus.

Authors:  J C Lee; S Takeda; P J Livolsi; L C Paoletti
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

8.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

9.  A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.

Authors:  A I Fattom; J Sarwar; A Ortiz; R Naso
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

10.  Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.

Authors:  A Fattom; R Schneerson; S C Szu; W F Vann; J Shiloach; W W Karakawa; J B Robbins
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.609

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.